1. Kashangura R, Julien S, Garner P, Johnson S. MVA85A vaccine to enhance BCG for preventing tuberculosis. CochraneDatabase of Systematic Reviews 2019, Issue 4. Art. No.: CD012915. DOI: 10.1002/14651858.CD012915.pub2
2. Kementerian Kesehatan Republik Indonesia. Indonesia Lakukan Tiga Uji Vaksin TBC. 2024. https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20240924/3146524/indonesia-lakukan-tiga-uji-vaksin-tbc/
3. Wang H, Wang S, Fang R, Li X, Xing J, Li Z, Song N. Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies. Vaccines (Basel). 2023 Dec 29;12(1):38. doi: 10.3390/vaccines12010038.
4. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta‐analysis. BMJ 2014;349:g4643
5. Altenburg AF, Kreijtz JH, Vries RD, Song F, Fux R, Rimmelzwaan GF, et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 2014;6(7):2735‐61
6. Nemes E, Hesseling A, Tameris M, et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases 2018;66(4):554–63. DOI: 10.1093/cid/cix834
7. Wajja A, Nassanga B, Natukunda A, et al; TB042 Study Team. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Lancet Infect Dis. 2024 Mar;24(3):285-296. doi: 10.1016/S1473-3099(23)00501-7.
8. Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med. 2019 Dec 19;381(25):2429-2439. doi: 10.1056/NEJMoa1909953.